Idera Pharmaceuticals, Inc. (IDRA) Announces Publication Of New Data Demonstrating Impact Of Inhibiting TLRs 7, 8, And 9 In A Preclinical Model Of Autoimmune Disease
1/22/2014 9:05:34 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced the publication of a study supporting the potential role of the suppression of Toll-like-receptors (TLRs) 7, 8, and 9 in the treatment of psoriasis. The data were published in the scientific journal PLOS ONE.
Help employers find you! Check out all the jobs and post your resume.
comments powered by